文献速递胸部肿瘤

厄洛替尼、卡博替尼或厄洛替尼联合卡博替尼作为EGFR野生型晚期非小细胞肺癌二线或三线治疗(ECOG-ACRIN 1512):一项随机、对照、开放标签、多中心、2期试验

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2016-11-04

该2期试验在美国37个肿瘤诊疗机构纳入EGFR野生型晚期非鳞非小细胞肺癌患者,随机分配至厄洛替尼单药、卡博替尼单药或厄洛替尼联合卡博替尼。与厄洛替尼单药相比,卡博替尼单药和联合组的无进展生存期均显著改善,联合组毒性增加但总体可控。

要点

  • 卡博替尼单药和厄洛替尼联合卡博替尼较厄洛替尼单药均显著改善无进展生存期。
  • 联合组3/4级腹泻发生率为28%,高于两单药组的8%。
  • 卡博替尼组发生1例呼吸衰竭死亡,联合组发生1例肺炎死亡。

核心结论

  • 尽管样本量小,该试验显示在EGFR野生型非小细胞肺癌患者中,卡博替尼单药或联合厄洛替尼的疗效优于厄洛替尼单药,具有临床意义,额外毒性总体可控。
  • 以卡博替尼为基础的治疗方案在该患者人群中值得进一步研究。

研究设计与样本

  • 研究为三组、随机、对照、开放标签、多中心2期试验,在美国37个学术和社区肿瘤诊疗机构进行。
  • 纳入既往接受过一或两种方案治疗的晚期非鳞状、EGFR野生型非小细胞肺癌患者。
  • 患者按体能状态和治疗线数分层,使用区组随机分配接受厄洛替尼150 mg每日口服、卡博替尼60 mg每日口服或厄洛替尼150 mg联合卡博替尼40 mg每日口服。
  • 主要终点为比较厄洛替尼单药组与卡博替尼单药组、以及厄洛替尼单药组与厄洛替尼联合卡博替尼组的无进展生存期,在意向性治疗人群(符合条件、随机分配并至少接受一剂治疗的患者)中评估。

主要发现

  • 2013年2月7日至2014年7月1日,共随机分配42例至厄洛替尼组、40例至卡博替尼组、43例至联合组,其中111例(89%)纳入主要分析(厄洛替尼组n=38,卡博替尼组n=38,联合组n=35)。
  • 与厄洛替尼单药组(中位1.8个月[95%CI 1.7-2.2])相比,卡博替尼组无进展生存期显著改善(4.3个月[3.6-7.4];HR 0.39,80%CI 0.27-0.55;单侧p=0.0003)。
  • 与厄洛替尼单药组相比,厄洛替尼联合卡博替尼组无进展生存期显著改善(4.7个月[2.4-7.4];HR 0.37,80%CI 0.25-0.53;单侧p=0.0003)。
  • 安全性分析人群中,最常见的3或4级不良事件为腹泻(厄洛替尼组3例[8%] vs 卡博替尼组3例[8%] vs 联合组11例[28%])、高血压(无 vs 10例[25%] vs 1例[3%])、乏力(5例[13%] vs 6例[15%] vs 6例[15%])、口腔黏膜炎(无 vs 4例[10%] vs 1例[3%])和血栓栓塞事件(无 vs 3例[8%] vs 2例[5%])。
  • 卡博替尼组发生1例呼吸衰竭死亡,认为可能与任一药物相关;联合组发生1例肺炎死亡,认为与任一药物或联合方案相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文自述样本量小(Despite its small sample size)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lung cancer tumorigenesis. We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. METHODS: This three group, randomised, controlled, open-label, multicentre, phase 2 trial was done in 37 academic and community oncology practices in the USA. Patients were eligible if they had received one or two previous treatments for advanced non-squamous, EGFR wild-type, NSCLC. Patients were stratified by performance status and line of therapy, and randomly assigned using permuted blocks within strata to receive open-label oral daily dosing of erlotinib (150 mg), cabozantinib (60 mg), or erlotinib (150 mg) and cabozantinib (40 mg). Imaging was done every 8 weeks. At the time of radiographic progression, there was optional crossover for patients in either single-drug group to receive combination treatment. The primary endpoint was to compare progression-free survival in patients given erlotinib alone versus cabozantinib alone, and in patients given erlotinib alone versus the combination of erlotinib plus cabozantinib. We assessed the primary endpoint in the per-protocol population, which was defined as all patients who were eligible, randomly assigned, and received at least one dose of treatment. The safety analysis population included all patients who received study treatment irrespective of eligibility. This trial is registered with ClinicalTrials.gov, number NCT01708954. FINDINGS: Between Feb 7, 2013, and July 1, 2014, we enrolled and randomly assigned 42 patients to erlotinib treatment, 40 patients to cabozantinib treatment, and 43 patients to erlotinib plus cabozantinib treatment, of whom 111 (89%) in total were included in the primary analysis (erlotinib [n=38], cabozantinib [n=38], erlotinib plus cabozantinib [n=35]). Compared with erlotinib alone (median 1·8 months [95% CI 1·7-2·2]), progression-free survival was significantly improved in the cabozantinib group (4·3 months [3·6-7·4]; hazard ratio [HR] 0·39, 80% CI 0·27-0·55; one-sided p=0·0003) and in the erlotinib plus cabozantinib group (4·7 months [2·4-7·4]; HR 0·37, 0·25-0·53; one-sided p=0·0003). Among participants included in the safety analysis of the erlotinib (n=40), cabozantinib (n=40), and erlotinib plus cabozantinib (n=39) groups, the most common grade 3 or 4 adverse events were diarrhoea (three [8%] cases in the erlotinib group vs three [8%] in the cabozantinib group vs 11 [28%] in the erlotinib plus cabozantinib group), hypertension (none vs ten [25%] vs one [3%]), fatigue (five [13%] vs six [15%] vs six [15%]), oral mucositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]). One death due to respiratory failure occurred in the cabozantinib group, deemed possibly related to either drug, and one death due to pneumonitis occurred in the erlotinib plus cabozantinib group, deemed related to either drug or the combination. INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. Cabozantinib-based regimens are promising for further investigation in this patient population. FUNDING: ECOG-ACRIN Cancer Research Group, National Cancer Institute of the National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Neal JW, Dahlberg SE, Wakelee HA, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016. PMID: 27825638. doi:10.1016/S1470-2045(16)30561-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。